- Home
- GMAB vs SN Comparison
GMAB vs SN Comparison
Compare GMAB & SN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- SN
- Stock Information
- Founded
- GMAB 1999
- SN 1993
- Country
- GMAB Denmark
- SN United States
- Employees
- GMAB N/A
- SN N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- SN
- Sector
- GMAB Health Care
- SN
- Exchange
- GMAB Nasdaq
- SN Nasdaq
- Market Cap
- GMAB 17.4B
- SN 13.0B
- IPO Year
- GMAB N/A
- SN N/A
- Fundamental
- Price
- GMAB $30.56
- SN $94.84
- Analyst Decision
- GMAB Strong Buy
- SN Strong Buy
- Analyst Count
- GMAB 6
- SN 7
- Target Price
- GMAB $40.40
- SN $126.29
- AVG Volume (30 Days)
- GMAB 2.5M
- SN 2.3M
- Earning Date
- GMAB 11-06-2025
- SN 11-06-2025
- Dividend Yield
- GMAB N/A
- SN N/A
- EPS Growth
- GMAB 132.41
- SN 58.74
- EPS
- GMAB 25.10
- SN 4.05
- Revenue
- GMAB $3,845,670,022.00
- SN $6,084,941,000.00
- Revenue This Year
- GMAB $24.92
- SN $18.26
- Revenue Next Year
- GMAB $15.97
- SN $11.75
- P/E Ratio
- GMAB $1.21
- SN $23.19
- Revenue Growth
- GMAB 29.57
- SN 18.87
- 52 Week Low
- GMAB $17.24
- SN $60.50
- 52 Week High
- GMAB $33.65
- SN $128.51
- Technical
- Relative Strength Index (RSI)
- GMAB 58.36
- SN 51.09
- Support Level
- GMAB $28.08
- SN $91.26
- Resistance Level
- GMAB $29.35
- SN $97.57
- Average True Range (ATR)
- GMAB 0.69
- SN 4.34
- MACD
- GMAB 0.03
- SN 1.03
- Stochastic Oscillator
- GMAB 95.93
- SN 61.99
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About SN SharkNinja Inc.
SharkNinja Inc is a product design and technology company that creates 5-star-rated lifestyle solutions through inventive products for consumers around the world. Its product categories include Cleaning, Cooking, Food Preparation, Home Environment and Beauty products. It sells vacuum cleaners, cooking pots, fryers, hair dryers, etc. The SharkNinja Group is expected to carry on the design, production, marketing, and distribution of the Shark and Ninja brands of small household appliances in North America, Europe and other selected international markets (excluding the Asia Pacific Region and Greater China). Currently, the majority of the revenue is derived from the U.S. market.